1. Introduction
===============

Gastric cancer (GC) is one of the most common causes of cancer-related deaths even with improvements in treatment modalities.^\[[@R1]\]^ The ability to predict the precise prognosis is critical for choosing the personally treatment plan and follow-up strategies for a patient. The established prognostic factors were tumor, node, tumor-node-metastasis (TNM) stage, and pathological type, etc.^\[[@R2]\]^ However, it was reported that even within the same tumor stage, the clinical outcomes of patients can be heterogeneous.^\[[@R3]\]^ This implies that further studies should be performed to find more prognostic factors for taking into account.

The role of the systemic inflammatory response in cancer has been highlighted in several studies.^\[[@R4]--[@R6]\]^ A significant association between elevated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with poor prognosis in various types of cancer has been shown.^\[[@R7]--[@R10]\]^ Compared with other factors, NLR and PLR are easily, routinely, and inexpensively obtained. Although several studies have valued the relationship between NLR, PLR, and the prognosis of GC, the prognostic importance of these inflammatory markers is still in controversy.

We conducted this study to evaluate the relationship between NLR, PLR, and survival of GC, and investigate the prognostic value of NLR and NLR in GC patients before treatment.

2. Materials and methods
========================

2.1. Study population
---------------------

This study included 182 histologically confirmed gastric adenocarcinoma cases, which were diagnosed in Kunshan First People\'s Hospital Affiliated to Jiangsu University between January 2011 and January 2014. Patients with incomplete follow-up data or active concurrent infection were excluded. At recruitment, personal data of each participant regarding clinical characters and survival information were collected from clinical record or family contact. The overall survival (OS) was defined as time from the data of diagnosis to the data of death or last visit. The progression-free survival (PFS) was calculated from the time of diagnosis to the time of progression, relapse, death, or the last follow-up. This prospective observational study was reviewed by our Institutional Review Board and written informed consent was provided by each patient.

2.2. Data collection
--------------------

Clinical characteristics including age, gender, surgery, chemotherapy, tumor location, clinical TNM stage, pathologic type as well as outcomes were collected. The tumors were staged according to the TNM staging system of the American Joint Committee on Cancer (AJCC 7th ed., 2010). The blood cell counts including neutrophil, platelets, and lymphocyte before treatment were extracted from the medical records. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. In the same way, PLR was defined as the absolute platelet count divided by the absolute lymphocyte count.

2.3. Statistical analysis
-------------------------

The optimal cutoff values of NLR and PLR were estimated by the receiver operating characteristics (ROC) curve. The area under the curve (AUC), sensitivity, and specificity were calculated. Continuous variables were expressed using mean ± SD. Comparisons between groups were performed using Chi-squared test. The Kaplan--Meier method and log-rank tests were used to compare survival curves. Moreover, we conducted multivariate analyses to assess the effects of multiple covariates on the survival outcome. Hazard ratios (HRs) estimated from the multivariable analysis were expressed as relative risks with 95% confidence interval (95% CI). For all the analyses, a 2-sided *P* value of \<.05 was defined as significant. Statistical analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL).

3. Results
==========

3.1. Clinicopathologic characteristics
--------------------------------------

The clinical/pathological characteristics of the 182 patients are summarized in Table [1](#T1){ref-type="table"}. Of 182 patients, 122 (67%) were male, and the median age was 65 years (range 29--87 years). Among all the cases, 56 (30.77%) patients were esophagogastric junction adenocarcinoma and 48 (26.37%) were diagnosed with gastric antrum cancer. Overall, 134 (73.63%) patients received surgical resection, and 151 (82.97%) patients received at least 1 cycle of chemotherapy. More than half (66.48%) of the patients were diagnosed of poorly differentiated adenocarcinoma, while the clinical stage III and IV patients were accounted for 48.90% and 22.53%, respectively.
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Association of the patients' characteristics with the platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios.

![](medi-97-e0144-g001)

3.2. The association between NLR or PLR and clinicopathologic variables
-----------------------------------------------------------------------

The optimal cutoff level for the NLR was 2.88 for both OS and PFS when the Youden index was maximal. Similarly, the cutoff level for the PLR was 172 for both OS and PFS (supplementary Figure 1--4). The NLR level before treatment was elevated in 98 (53.85%) patients and a total of 64 (35.16%) patients were with higher PLR level. As summarized in Table [1](#T1){ref-type="table"}, increased NLR level was significantly associated with age (*P* = .026), surgery (*P* = .006), node status (*P* = .004), and clinical stage (*P* = .009). However, PLR was not associated with age, sex, surgery, tumor location, histological type, or clinical stage.

3.3. Prognostic factors for OS and PFS
--------------------------------------

In this study, the median OS for all patients was 28.5 months, while PFS was 19.5 months. We further found that the median OS and PFS were poor in the High-NLR group (OS: 36.0 vs 20.5 months, *P* \< .001, PFS: 33.0 versus 12.0 months, *P* \< .001) and High-PLR group (OS: 31.5 vs 18.5 months, *P* *=* .003, PFS: 26.0 versus 11.0 months, *P* *=* .01), as shown in Figure ([1](#F1){ref-type="fig"}--[4](#F4){ref-type="fig"}).
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The prognostic effect of clinicopathologic variables is summarized in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. In univariate analysis, the older age (*P* *=* .002), no surgery (*P* \< .001), poorly differentiated histologic type (*P* *=* .048), advanced T (*P* \< .001), N (*P* \< .001) and clinical stage (*P* \< .001), higher NLR (*P* \< .001) and higher PLR (*P* *=* .004) were identified as poor prognostic factors associated with OS. Although no surgery (*P* \< .001), advanced T (*P* \< .001), N (*P* \< .001) and clinical stage (*P* \< .001), higher NLR (*P* \< .001) and higher PLR (*P* *=* .012) were also associated with poor PFS. After multivariate analysis with these selected parameters using Cox regression model, both surgery (HR = 2.092, 95% CI: 1.345--3.253, *P* *=* .001) and NLR (HR = 1.585, 95% CI: 1.011--2.485, *P* *=* .045) were identified as independent prognostic factors associated with OS.
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Univariate and multivariate analyses of factors for the prediction of overall survival.
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Univariate and multivariate analyses of factors for the prediction of progression-free survival.
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4. Discussion
=============

This study investigated the prognostic value of NLR and PLR in GC patients before treatment. We found that a high NLR was associated with age, surgery, node status, and clinical stage. Similar to previous studies, both the elevated NLR and PLR levels predicted poor OS and PFS in GC patients.^\[[@R11],[@R12]\]^ NLR was an independent risk factor for OS in Cox regression analysis.

Many types of cancer were proved to have links with infection and inflammatory reaction, such as GC. *Helicobacter pylori* infection is characterized by an inflammatory infiltrate, consisting mainly of neutrophils and T cells.^\[[@R13]\]^ The inflammation reaction is an important factor in tumor cell microenvironment.^\[[@R14],[@R15]\]^ The inflammatory cells, chemokines, and cytokines are responsible for cell proliferation, angiogenesis, invasion, and metastasis.^\[[@R16]\]^ The inflammation results are involved in lymphocytopenia, neutrophilia, and thrombocytosis.^\[[@R17],[@R18]\]^ The lymphocyte response plays an important role in immune responses, and it is also a major factor in the suppression of cancer progression.^\[[@R19]\]^ The mechanisms of neutrophilia in proliferation and metastasis include release of reactive oxygen species or nitric oxide and remodeling of the extracellular matrix.^\[[@R20]\]^ Platelets might participate in the inflammatory reaction by increasing angiogenesis or releasing growth factors.^\[[@R21],[@R22]\]^

The concept of inflammation-based scores, such as the NLR and PLR, has been revealed as negative prognostic factors in various types of solid tumors, such as breast cancer,^\[[@R7]\]^ colorectal cancer,^\[[@R23],[@R24]\]^ esophageal squamous cell carcinoma,^\[[@R25]\]^ liver cancer,^\[[@R26]\]^ and combined small cell lung cancer.^\[[@R27]\]^ Several studies also focused on the association between NLR, PLR, and GC.^\[[@R28]--[@R30]\]^ A meta-analysis including 10 studies with a total of 2952 cases indicated that elevated NLR predicated poor survival in GC.^\[[@R31]\]^ Dogan et al^\[[@R32]\]^ found that patients with high PLR and/or NLR have shorter PFS and OS in metastatic GC receiving first-line modified docetaxel, cisplatin, and 5-fluorouracil (mDCF). Deng et al^\[[@R30]\]^ reported that preoperative NLR may serve as potential prognostic biomarkers in patients with GC who underwent surgical resection; however, they did not find that NLR was significantly associated with OS (*P* = .648) in multivariate analysis. Due to the differences in assays measuring neutrophil and lymphocyte, different population and different survival end-point, we optimized the algorithm results and employed different cut-off values. Fortunately, our results have shown that NLR was the independent prognostic factor for OS (*P* = .045) in multivariate analysis.

Some researchers also compared the prognostic value of NLR and PLR. Kim et al^\[[@R12]\]^ reported that although both the NLR and PLR can reflect the prognosis, the NLR is more predictive of OS than the PLR. In Our study, we also found that higher NLR and higher PLR were associated with poor OS and PFS. After multivariate analysis, only NLR was identified as an independent prognostic factor for OS. We supposed that NLR has more predictive value than PLR. As NLR is the ratio of neutrophils to lymphocytes, high NLR means a relatively higher neutrophils and lower lymphocyte levels. A high NLR indicated an imbalance in the immune response, which impaired the normal anti-tumor functions.^\[[@R20]\]^ Thus, tumor recurrence and invasion may occur. Given that some potential limitations exist in the present study, bias is inevitable. This retrospective study was conducted in 1 single institution, and some potential cofactors related to systematic inflammation and immunity have not been considered in all analyses. Our results still need more evidences to support.

In conclusion, high level of NLR and PLR was associated with poor OS and PFS in GC patients. NLR was identified as an independent prognostic factor for GC patients. Larger, prospective, and randomized studies are needed to confirm these findings and to elucidate the potential mechanism of systemic inflammatory response against tumor cells.
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